Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy

Lung Cancer

Volumn 68, Issue 2, 2010, Pages 288-294

  Jeong, Seong Hyun ^a   Jung, Jae Ho ^a   Han, Jae Ho ^a   Kim, Jang Hee ^a   Choi, Yong Won ^a   Lee, Hyun Woo ^a   Kang, Seok Yun ^a   Hwang, Yoon Ho ^a   Ahn, Mi Sun ^a   Choi, Jin Hyuk ^a   Oh, Young Taek ^a   Chun, Mison ^a   Kang, Seunghee ^a   Park, Kwang Joo ^a   Hwang, Sung Chul ^a   Sheen, Seung Soo ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Bcl 2; Chemoradiotherapy; Non small cell lung cancer (NSCLC); Prognosis

Indexed keywords

CISPLATIN; DOCETAXEL; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; IFOSFAMIDE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION; TREATMENT OUTCOME; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE PROGRESSION; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77950461118     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.06.003     Document Type: Article

References (47)

1. Bae J.M., Won Y.J., Jung K.W., Suh K.-A., Yun Y.-H., Shin M.-H. Survival of Korean cancer patients diagnosed in 1995. Cancer Res Treat 2002, 34:319-325.
2. Spira A., Ettinger D.S. Multidisciplinary management of lung cancer. N Engl J Med 2004, 350:379-392.
3. Blackstock A.W., Govindan R. Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. J Clin Oncol 2007, 25:4146-4152.
4. Penland S.K., Socinski M.A. Management of unresectable stage III non-small cell lung cancer: the role of combined chemoradiation. Semin Radiat Oncol 2004, 14:326-334.
5. Rigas J.R., Kelly K. Current treatment paradigms for locally advanced non-small cell lung cancer. J Thorac Oncol 2007, 2(SUPP1. 2):S77-85.
6. Gonzalez V.M., Fuertes M.A., Alonso C., Perez J.M. Is cisplatin-induced cell death always produced by apoptosis?. Mol Pharmacol 2001, 59:657-663.
7. Fulda S., Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-4811.
8. Reed J.C. Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ 2006, 13:1378-1386.
9. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
10. Reardon J.T., Vaisman A., Chaney S.G., Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 1999, 59:3968-3971.
11. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 2005, 11:6100-6102.
12. Murray D., Vallee-Lucic L., Rosenberg E., Andersson B. Sensitivity of nucleotide excision repair-deficient human cells to ionizing radiation and cyclophosphamide. Anticancer Res 2002, 22:21-26.
13. Viktorsson K., De Petris L., Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun 2005, 331:868-880.
14. Lee H.W., Choi J.H., Lim H.Y., Park J.S., Kim H.C., Kang S., et al. The addition of induction chemotherapy with etoposide, ifosfamide, and cisplatin failed to improve therapeutic outcome of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer-single institution retrospective analysis. Neoplasma 2006, 53:30-36.
15. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 1997, 111:1710-1717.
16. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
17. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
18. Kaplan E.M.P. Non-parametric estimations from incomplete observations. Am Stat Assoc 1958, 53:457-481.
19. Cox D.R. Regression model and life-tables. J Roy Stat Soc Ser 1972, 34:187-220.
20. Mitsudomi T., Hamajima N., Ogawa M., Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000, 6:4055-4063.
21. Singhal S., Vachani A., Antin-Ozerkis D., Kaiser L.R., Albelda S.M. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 2005, 11:3974-3986.
22. Steels E., Paesmans M., Berghmans T., Branle F., Lemaitre F., Mascaux C., et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001, 18:705-719.
23. Gessner C., Liebers U., Kuhn H., Stiehl P., Witt C., Schauer J., et al. BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer. Eur Respir J 2002, 19:134-140.
24. Azuma K., Komohara Y., Sasada T., Terazaki Y., Ikeda J., Hoshino T., et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 2007, 98:1336-1343.
25. Ceppi P., Volante M., Novello S., Rapa I., Danenberg K.D., Danenberg P.V., et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006, 17:1818-1825.
26. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002, 8:2286-2291.
27. Hwang I.G., Ahn M.J., Park B.B., Ahn Y.C., Han J., Lee S., et al. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 2008, 113:1379-1386.
28. Azuma K., Sasada T., Kawahara A., Hattori S., Kinoshita T., Takamori S., et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cancer Chemother Pharmacol 2009, [Epub].
29. Brooks K.R., To K., Joshi M.B., Conlon D.H., Herndon J.E., D'Amico T.A., et al. Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. Ann Thorac Surg 2003, 76:187-193. [discussion 193].
30. Fokkema E., Timens W., de Vries E.G., de Jong S., Fidler V., Meijer C., et al. Expression and prognostic implications of apoptosis-related proteins in locally unresectable non-small cell lung cancers. Lung Cancer 2006, 52:241-247.
31. Hwang J.H., Lim S.C., Kim Y.C., Park K.O., Ahn S.J., Chung W.K. Apoptosis and bcl-2 expression as predictors of survival in radiation-treated non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001, 50:13-18.
32. Martin B., Paesmans M., Berghmans T., Branle F., Ghisdal L., Mascaux C., et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2003, 89:55-64.
33. Paul J.M., van de Vaart J.B., de Jong D., Sneeuw K.C.A., Majoor D., Bartelink H., et al. Begg DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 2000, 89:160-166.
34. Pezzella F., Turley H., Kuzu I., Tungekar M.F., Dunnill M.S., Pierce C.B., et al. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993, 329:690-694.
35. Raouf AA E.D., Carton E., Mulligan E., Griffin M.M., Reynolds J.V. Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation. Dis Esophagus 2003, 16:17-23.
36. Homma A., Furuta Y., Oridate N., Nakano Y., Kohashi G., Yagi K., et al. Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Clin Cancer Res 1999, 5:801-806.
37. Keam B., Im S.A., Kim H.J., Oh D.Y., Kim J.H., Lee S.H., et al. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 2007, 7:203.
38. Cheng E.H., Kirsch D.G., Clem R.J., Ravi R., Kastan M.B., Bedi A., et al. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 1997, 278:1966-1968.
39. Del Bello B., Valentini M.A., Zunino F., Comporti M., Maellaro E. Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells. Oncogene 2001, 20:4591-4595.
40. Kirsch D.G., Doseff A., Chau B.N., Lim D.S., de Souza-Pinto N.C., Hansford R., et al. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J Biol Chem 1999, 274:21155-21161.
41. Certo M., Del Giazo Moore V., Nishino M., Wei G., Korsmeyer S., Armstrong S.A., et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006, 351-365.
42. Brunelle J.K., Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 2009, 122:437-441.
43. Boldrini L., Calcinai A., Samaritani E., Pistolesi F., Mussi A., Lucchi M., et al. Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. Br J Cancer 2000, 83:480-486.
44. Fontanini G., Boldrini L., Vignati S., Chine S., Basolo F., Silvestri V., et al. Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. Eur J Cancer 1998, 34:718-723.
45. Koukourakis M.I., Giatromanolaki A., O'Byrne K.J., Whitehouse R.M., Talbot D.C., Gatter K.C., et al. Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer. Int J Cancer 1997, 74:565-570.
46. Koukourakis M.I., Giatromanolaki A., O'Byrne K.J., Cox J., Krammer B., Gatter K.C., et al. Bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer. Clin Exp Metastasis 1999, 17:545-554.
47. Solan M.J., Werner-Wasik M. Prognostic factors in non-small cell lung cancer. Semin Surg Oncol 2003, 21:64-73.